<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080831</url>
  </required_header>
  <id_info>
    <org_study_id>17/4/34</org_study_id>
    <nct_id>NCT03080831</nct_id>
  </id_info>
  <brief_title>TOnicity of Perioperative Maintenance SoluTions</brief_title>
  <acronym>TOPMAST-1</acronym>
  <official_title>TOnicity of Perioperative Maintenance SoluTions - Part 1: Thoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niels Van Regenmortel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized double blind phase IV trial studying the efficacy and safety of the
      tonicity of two different perioperative maintenance solutions: an isotonic solution
      containing NaCl 0.9 in glucose 5% with an added 40 mmol/L of potassium or a commercially
      available premixed solution (Glucion 5%) containing a.o. 54 mmol/L of sodium and 26 mmol/L of
      potassium. Both solutions are administered at 27 mL/kg of ideal body weight, as recommended
      by current guidelines (NICE 174) and both solutions are widely used in daily clinical
      practice. The primary hypothesis is that isotonic maintenance solutions lead to more fluid
      retention than hypotonic fluids. Metabolism of both solutions is assessed by sequential
      analysis of urine and serum and clinical parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study fluids blinded using opaque bags</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fluid balance</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery)</time_frame>
    <description>Difference between all fluid intake and output</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resuscitation Fluids</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery)</time_frame>
    <description>The cumulative amount of additional (resuscitation) fluids during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor Use</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery)</time_frame>
    <description>The cumulative amount of vasopressors during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Mechanisms: Aldosterone level</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Change from baseline aldosterone level at start of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Mechanisms: Fractional Excretion of Sodium</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Change from baseline FeNa at start of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolyte Homeostasis and Disorders: Sodium</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Mean sodium level and change from baseline. Occurrence of hypo and hypernatremia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolyte Homeostasis and Disorders: Potassium</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Mean potassium level and change from baseline. Occurrence of hypo and hyperpotassemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolyte Homeostasis and Disorders: Chloride</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Mean chloride level and change from baseline. Occurrence of hypo and hyperchloremia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolyte Homeostasis and Disorders: Strong Ion Difference</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Mean SID level and change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolyte Homeostasis and Disorders: Phosphate</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Mean phosphate level and change from baseline. Occurrence of hypo and hyperphosphatemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolyte Homeostasis and Disorders: Calcium</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Mean calcium level and change from baseline. Occurrence of hypo and hypercalcemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Endpoints: paO2/FiO2</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery) - Assessments at fixed time points.</time_frame>
    <description>Mean postoperative paO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Endpoints: occurrence of de novo atrial fibrillation</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery). Continuous assessment.</time_frame>
    <description>occurrence of de novo atrial fibrillation (Y/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Endpoints: occurrence of acute kidney injury (AKI)</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery). Continuous assessment.</time_frame>
    <description>AKI according to RIFLE-score creatinine and urine R-I-F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium balance</measure>
    <time_frame>From start of surgery until end of study, defined as one of the following (1) discharge from ICU (2) 8AM on third postoperative day (maximum: up to 72h after start of surgery).</time_frame>
    <description>Sodium balance (total in vs out) at end of study, assessed by urine collection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Thoracic Diseases</condition>
  <condition>Water-Electrolyte Imbalance</condition>
  <condition>Fluid Overload</condition>
  <condition>Fluid Retention</condition>
  <condition>Sodium Disorder</condition>
  <condition>Potassium Disorders</condition>
  <condition>Chloride Disorder</condition>
  <arm_group>
    <arm_group_label>NaCl 0.9% in Glucose 5% + 40mmol/L Potassium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucion 5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9% in Glucose 5% + 40mmol/L Potassium</intervention_name>
    <description>Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.</description>
    <arm_group_label>NaCl 0.9% in Glucose 5% + 40mmol/L Potassium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucion 5%</intervention_name>
    <description>Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.</description>
    <arm_group_label>Glucion 5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (at least 18 y.o.)

          -  Undergoing elective lung resection (wedge resection, segmental resection,
             (bi)lobectomy, but not pneumonectomy) via thoracotomy or video- or robot assisted
             (VATS, RATS)

          -  Normal renal function (eGFR &gt;60 ml/min/1.73mÂ² (CKD-EPI))

        Exclusion Criteria:

          -  Under chronic treatment with diuretics or desmopressin

          -  Heart failure (NYHA III-IV)

          -  Liver Failure

          -  Brittle diabetes mellitus

          -  Neurological contra-indication for hypotonic fluids

          -  SIADH or hyponatremia &lt;130 or &gt; 150 mmol/L at preoperative assessment

          -  Hyperkalemia &gt; 5 mmol/L at preoperative assessment

          -  Under treatment with artificial nutrition (enteral or parenteral)

          -  Pregnancy

        Additional pre-defined exclusion after initial inclusion

          -  Massive perioperative transfusion or intraoperative resuscitation of +2.5L of
             crystalloids/colloids

          -  Absence of admission to ICU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital, Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Van Regenmortel, M.D.</last_name>
      <phone>0032484770751</phone>
      <email>niels.vanregenmortel@uza.be</email>
    </contact>
    <contact_backup>
      <last_name>Philippe Jorens, M.D.;Ph.D.</last_name>
      <phone>003232173639</phone>
      <email>philippe.jorens@uza.be</email>
    </contact_backup>
    <investigator>
      <last_name>Niels Van Regenmortel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://guidance.nice.org.uk/CG174</url>
    <description>NICE guideline on Intravenous Fluid Therapy in Adults in Hospital</description>
  </link>
  <link>
    <url>http://www.bapen.org.uk/pdfs/bapen_pubs/giftasup.pdf</url>
    <description>GIFTASUP guidelines</description>
  </link>
  <reference>
    <citation>Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002 May 25;359(9320):1812-8.</citation>
    <PMID>12044376</PMID>
  </reference>
  <reference>
    <citation>Moritz ML, Ayus JC. Maintenance Intravenous Fluids in Acutely Ill Patients. N Engl J Med. 2015 Oct;373(14):1350-60. doi: 10.1056/NEJMra1412877. Review.</citation>
    <PMID>26422725</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Niels Van Regenmortel</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Maintenance Fluid Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Thoracic Diseases</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Water-Electrolyte Imbalance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Anonymized data available on reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

